Published in Am J Physiol Heart Circ Physiol on August 17, 2012
Monocyte and macrophage heterogeneity in the heart. Circ Res (2013) 1.63
Myofibroblasts and the extracellular matrix network in post-myocardial infarction cardiac remodeling. Pflugers Arch (2014) 0.98
Targeting matrix metalloproteinases in heart disease: lessons from endogenous inhibitors. Biochem Pharmacol (2014) 0.95
Acetylsalicylic acid inhibits IL-18-induced cardiac fibroblast migration through the induction of RECK. J Cell Physiol (2014) 0.91
Aliskiren and valsartan mediate left ventricular remodeling post-myocardial infarction in mice through MMP-9 effects. J Mol Cell Cardiol (2014) 0.91
Regulation of connective tissue growth factor gene expression and fibrosis in human heart failure. J Card Fail (2013) 0.90
TIMP-1 gene polymorphism: are genetics able to predict outcome of septic patients? Crit Care (2013) 0.89
The enduring importance of animal models in understanding periodontal disease. Virulence (2015) 0.87
Matrix metalloproteinases as potential targets in the venous dilation associated with varicose veins. Curr Drug Targets (2013) 0.87
Matrix metalloproteinases as input and output signals for post-myocardial infarction remodeling. J Mol Cell Cardiol (2015) 0.84
Translating Koch's postulates to identify matrix metalloproteinase roles in postmyocardial infarction remodeling: cardiac metalloproteinase actions (CarMA) postulates. Circ Res (2014) 0.84
Mechanistic relationship between membrane type-1 matrix metalloproteinase and the myocardial response to pressure overload. Circ Heart Fail (2014) 0.83
The pore-forming toxin listeriolysin O is degraded by neutrophil metalloproteinase-8 and fails to mediate Listeria monocytogenes intracellular survival in neutrophils. J Immunol (2013) 0.82
Matrix Metalloproteinases in Non-Neoplastic Disorders. Int J Mol Sci (2016) 0.81
Redox-relevant aspects of the extracellular matrix and its cellular contacts via integrins. Antioxid Redox Signal (2014) 0.81
Using systems biology approaches to understand cardiac inflammation and extracellular matrix remodeling in the setting of myocardial infarction. Wiley Interdiscip Rev Syst Biol Med (2014) 0.80
Activation of GPR30 inhibits cardiac fibroblast proliferation. Mol Cell Biochem (2015) 0.79
Matrix metalloproteinases and genetic mouse models in cancer research: a mini-review. Tumour Biol (2014) 0.78
Matrix metalloproteinases in neural development: a phylogenetically diverse perspective. Neural Regen Res (2016) 0.77
Unbiased analysis of senescence associated secretory phenotype (SASP) to identify common components following different genotoxic stresses. Aging (Albany NY) (2016) 0.77
Serotonin-Exacerbated DSS-Induced Colitis Is Associated with Increase in MMP-3 and MMP-9 Expression in the Mouse Colon. Mediators Inflamm (2016) 0.77
MMP-9 signaling in the left ventricle following myocardial infarction. Am J Physiol Heart Circ Physiol (2016) 0.76
Matrix Metalloproteinase-9 Production following Cardiopulmonary Bypass Was Not Associated with Pulmonary Dysfunction after Cardiac Surgery. Mediators Inflamm (2015) 0.76
Isolation and characterization of chicken bile matrix metalloproteinase. Poult Sci (2014) 0.76
Matrix metalloproteinase inhibitors based on the 3-mercaptopyrrolidine core. J Med Chem (2013) 0.76
Collapsed Reticular Network and its Possible Mechanism during the Initiation and/or Progression of Hepatic Fibrosis. Sci Rep (2016) 0.75
Experimental Dissection of Metalloproteinase Inhibition-Mediated and Toxic Effects of Phenanthroline on Zebrafish Development. Int J Mol Sci (2016) 0.75
Low levels of tissue inhibitor of metalloproteinase-2 at birth may be associated with subsequent development of bronchopulmonary dysplasia in preterm infants. Korean J Pediatr (2015) 0.75
Vascular Matrix Metalloproteinase Inhibition, a New Mechanism for How Peroxisome Proliferator-Activated Receptor-γ Protects Target Organ Damage. Hypertension (2015) 0.75
Aberrant gene expression of heparanase in ventricular hypertrophy induced by monocrotaline in rats. J Vet Med Sci (2015) 0.75
Acknowledged signatures of matrix metalloproteinases in Takayasu's arteritis. Biomed Res Int (2014) 0.75
Matrix metalloproteinase-targeted imaging of lung inflammation and remodeling. J Nucl Med (2016) 0.75
Adult and cord blood endothelial progenitor cells have different gene expression profiles and immunogenic potential. Blood Transfus (2013) 0.75
Carbonic anhydrase enzyme as a potential therapeutic target for experimental trichinellosis. Parasitol Res (2016) 0.75
New functions for the matrix metalloproteinases in cancer progression. Nat Rev Cancer (2002) 24.71
How matrix metalloproteinases regulate cell behavior. Annu Rev Cell Dev Biol (2001) 14.05
Matrix metalloproteinases: regulators of the tumor microenvironment. Cell (2010) 12.90
Matrix metalloproteinase inhibitors and cancer: trials and tribulations. Science (2002) 12.29
Increased expression of matrix metalloproteinases and matrix degrading activity in vulnerable regions of human atherosclerotic plaques. J Clin Invest (1994) 7.25
Collagenolytic activity in amphibian tissues: a tissue culture assay. Proc Natl Acad Sci U S A (1962) 5.94
Tumour microenvironment - opinion: validating matrix metalloproteinases as drug targets and anti-targets for cancer therapy. Nat Rev Cancer (2006) 5.58
Myocardial matrix remodeling and the matrix metalloproteinases: influence on cardiac form and function. Physiol Rev (2007) 4.69
Regulation of matrix metalloproteinases: an overview. Mol Cell Biochem (2003) 4.33
Tumor cell traffic through the extracellular matrix is controlled by the membrane-anchored collagenase MT1-MMP. J Cell Biol (2004) 4.16
H-ras oncogene-transformed human bronchial epithelial cells (TBE-1) secrete a single metalloprotease capable of degrading basement membrane collagen. J Biol Chem (1988) 4.06
Processing of VEGF-A by matrix metalloproteinases regulates bioavailability and vascular patterning in tumors. J Cell Biol (2005) 4.03
Intestinal tumorigenesis is suppressed in mice lacking the metalloproteinase matrilysin. Proc Natl Acad Sci U S A (1997) 3.96
MicroRNAs add a new dimension to cardiovascular disease. Circulation (2010) 3.64
Neutrophil granules and secretory vesicles in inflammation. Microbes Infect (2003) 3.56
Stromelysin, a connective tissue-degrading metalloendopeptidase secreted by stimulated rabbit synovial fibroblasts in parallel with collagenase. Biosynthesis, isolation, characterization, and substrates. J Biol Chem (1985) 3.51
Tadpole collagenase. Preparation and purification. Biochemistry (1966) 3.50
The tissue inhibitors of metalloproteinases (TIMPs): an ancient family with structural and functional diversity. Biochim Biophys Acta (2010) 3.33
The many faces of metalloproteases: cell growth, invasion, angiogenesis and metastasis. Trends Cell Biol (2001) 3.22
Generation of biologically active IL-1 beta by matrix metalloproteinases: a novel caspase-1-independent pathway of IL-1 beta processing. J Immunol (1998) 3.04
The membrane-anchored MMP inhibitor RECK is a key regulator of extracellular matrix integrity and angiogenesis. Cell (2001) 2.97
Potential therapeutic targets for cardiac fibrosis: TGFbeta, angiotensin, endothelin, CCN2, and PDGF, partners in fibroblast activation. Circ Res (2010) 2.89
Multiple modes of activation of latent human fibroblast collagenase: evidence for the role of a Cys73 active-site zinc complex in latency and a "cysteine switch" mechanism for activation. Proc Natl Acad Sci U S A (1990) 2.68
Enamelysin (matrix metalloproteinase 20)-deficient mice display an amelogenesis imperfecta phenotype. J Biol Chem (2002) 2.59
Inflammation in atherosclerosis: visualizing matrix metalloproteinase action in macrophages in vivo. Circulation (2006) 2.56
Stromelysin is an activator of procollagenase. A study with natural and recombinant enzymes. Biochem J (1987) 2.54
Chemokine and cytokine processing by matrix metalloproteinases and its effect on leukocyte migration and inflammation. J Leukoc Biol (2007) 2.36
Structural basis for the highly selective inhibition of MMP-13. Chem Biol (2005) 2.33
Evidence that latent collagenases are enzyme-inhibitor complexes. Biochem J (1977) 2.32
Human neutrophils uniquely release TIMP-free MMP-9 to provide a potent catalytic stimulator of angiogenesis. Proc Natl Acad Sci U S A (2007) 2.27
Purification and characterization of a rabbit bone metalloproteinase that degrades proteoglycan and other connective-tissue components. Biochem J (1983) 2.17
Macrophage roles following myocardial infarction. Int J Cardiol (2008) 2.14
Matrix metalloproteinase 2 from human rheumatoid synovial fibroblasts. Purification and activation of the precursor and enzymic properties. Eur J Biochem (1990) 2.13
Osteopontin, a novel substrate for matrix metalloproteinase-3 (stromelysin-1) and matrix metalloproteinase-7 (matrilysin). J Biol Chem (2001) 2.12
The other side of MMPs: protective roles in tumor progression. Cancer Metastasis Rev (2007) 2.07
Catabolism of collagen and non-collagen protein in the rat uterus during post-partum involution. Biochem J (1962) 2.06
Matrix metalloproteinases: what do they not do? New substrates and biological roles identified by murine models and proteomics. Biochim Biophys Acta (2009) 2.04
Selective inhibition of matrix metalloproteinase-14 blocks tumor growth, invasion, and angiogenesis. Cancer Res (2009) 2.03
Matrix metalloproteinase-13/collagenase-3 deletion promotes collagen accumulation and organization in mouse atherosclerotic plaques. Circulation (2005) 2.01
Human neutrophil collagenase. A distinct gene product with homology to other matrix metalloproteinases. J Biol Chem (1990) 1.98
Matrix metalloproteinases: roles in cancer and metastasis. Front Biosci (2006) 1.96
Matrilysin is expressed by lipid-laden macrophages at sites of potential rupture in atherosclerotic lesions and localizes to areas of versican deposition, a proteoglycan substrate for the enzyme. Proc Natl Acad Sci U S A (1996) 1.92
Molecular cloning and characterization of human tissue inhibitor of metalloproteinase 4. J Biol Chem (1996) 1.92
Tumor necrosis factor-alpha converting enzyme. Int J Biochem Cell Biol (2002) 1.83
Noninvasive targeted imaging of matrix metalloproteinase activation in a murine model of postinfarction remodeling. Circulation (2005) 1.82
Kinetic analysis of the binding of human matrix metalloproteinase-2 and -9 to tissue inhibitor of metalloproteinase (TIMP)-1 and TIMP-2. J Biol Chem (1997) 1.81
MicroRNA-27b regulates the expression of matrix metalloproteinase 13 in human osteoarthritis chondrocytes. Arthritis Rheum (2010) 1.78
microRNA-146b inhibits glioma cell migration and invasion by targeting MMPs. Brain Res (2009) 1.76
Processing, shedding, and endocytosis of membrane type 1-matrix metalloproteinase (MT1-MMP). J Cell Physiol (2004) 1.75
Angiostatin-converting enzyme activities of human matrilysin (MMP-7) and gelatinase B/type IV collagenase (MMP-9). J Biol Chem (1997) 1.75
A key role for mast cell chymase in the activation of pro-matrix metalloprotease-9 and pro-matrix metalloprotease-2. J Biol Chem (2004) 1.70
Analyses of all matrix metalloproteinase members in leukocytes emphasize monocytes as major inflammatory mediators in multiple sclerosis. Brain (2003) 1.67
Bone marrow molecular alterations after myocardial infarction: Impact on endothelial progenitor cells. Cardiovasc Res (2006) 1.65
Cardiac matrix metalloproteinase-2 expression independently induces marked ventricular remodeling and systolic dysfunction. Am J Physiol Heart Circ Physiol (2006) 1.63
The matrix metalloproteinase matrilysin influences early-stage mammary tumorigenesis. Cancer Res (1998) 1.60
The zymogen of tadpole collagenase. Biochemistry (1971) 1.56
Assessment of the multiple-biomarker approach for diagnosis of myocardial infarction in patients presenting with symptoms suggestive of acute coronary syndrome. Clin Chem (2008) 1.55
Clinical implications of elevated serum interleukin-6, soluble CD40 ligand, metalloproteinase-9, and tissue inhibitor of metalloproteinase-1 in patients with acute ST-segment elevation myocardial infarction. Clin Cardiol (2008) 1.54
Substrate hydrolysis by matrix metalloproteinase-9. J Biol Chem (2001) 1.54
OxLDL up-regulates microRNA-29b, leading to epigenetic modifications of MMP-2/MMP-9 genes: a novel mechanism for cardiovascular diseases. FASEB J (2011) 1.53
Intracellular substrate cleavage: a novel dimension in the biochemistry, biology and pathology of matrix metalloproteinases. Crit Rev Biochem Mol Biol (2010) 1.49
Accelerated LV remodeling after myocardial infarction in TIMP-1-deficient mice: effects of exogenous MMP inhibition. Am J Physiol Heart Circ Physiol (2005) 1.47
Matrix metalloproteinase-7 affects connexin-43 levels, electrical conduction, and survival after myocardial infarction. Circulation (2006) 1.46
Pleiotropic roles of matrix metalloproteinases in tumor angiogenesis: contrasting, overlapping and compensatory functions. Biochim Biophys Acta (2009) 1.46
Deficiency of TIMP-1 exacerbates LV remodeling after myocardial infarction in mice. Am J Physiol Heart Circ Physiol (2002) 1.45
Proteomic analysis identifies in vivo candidate matrix metalloproteinase-9 substrates in the left ventricle post-myocardial infarction. Proteomics (2010) 1.42
Matrix metalloproteinase 9 (MMP-9/gelatinase B) proteolytically cleaves ICAM-1 and participates in tumor cell resistance to natural killer cell-mediated cytotoxicity. Oncogene (2002) 1.42
Matrix metalloproteinases as therapeutic targets in cancer. Curr Cancer Drug Targets (2005) 1.42
Heterogeneous effects of tissue inhibitors of matrix metalloproteinases on cardiac fibroblasts. Am J Physiol Heart Circ Physiol (2005) 1.40
Inhibition of matrix metalloproteinase 14 (MMP-14)-mediated cancer cell migration. J Biol Chem (2011) 1.40
The importance of estimating the therapeutic index in the development of matrix metalloproteinase inhibitors. Cardiovasc Res (2006) 1.40
Matrix metalloproteinase-2 and myocardial oxidative stress injury: beyond the matrix. Cardiovasc Res (2009) 1.39
Temporal and spatial expression of matrix metalloproteinases and tissue inhibitors of metalloproteinases following myocardial infarction. Cardiovasc Ther (2010) 1.39
Tissue inhibitor of metalloproteinases-2 (TIMP-2) suppresses TKR-growth factor signaling independent of metalloproteinase inhibition. J Biol Chem (2000) 1.39
A new class of potent matrix metalloproteinase 13 inhibitors for potential treatment of osteoarthritis: Evidence of histologic and clinical efficacy without musculoskeletal toxicity in rat models. Arthritis Rheum (2009) 1.38
A specific inhibitor of vertebrate collagenase produced by human skin fibroblasts. J Biol Chem (1979) 1.37
Discovery and characterization of a novel inhibitor of matrix metalloprotease-13 that reduces cartilage damage in vivo without joint fibroplasia side effects. J Biol Chem (2007) 1.37
Molecular imaging of activated matrix metalloproteinases in vascular remodeling. Circulation (2008) 1.37
Murine tissue inhibitor of metalloproteinases-4 (Timp-4): cDNA isolation and expression in adult mouse tissues. FEBS Lett (1997) 1.36
TIMP-3 deficiency leads to dilated cardiomyopathy. Circulation (2004) 1.36
Type I collagen is a genetic modifier of matrix metalloproteinase 2 in murine skeletal development. Dev Dyn (2007) 1.35
Matrix metalloproteinase inhibitors: a critical appraisal of design principles and proposed therapeutic utility. Drugs (2010) 1.35
Tissue inhibitor of metalloproteinase-1 (TIMP-1) is an independent predictor of all-cause mortality, cardiac mortality, and myocardial infarction. Am Heart J (2006) 1.31
Identification of specific hemopexin-like domain residues that facilitate matrix metalloproteinase collagenolytic activity. J Biol Chem (2009) 1.30
Resistance of collagenase-2 (matrix metalloproteinase-8)-deficient mice to TNF-induced lethal hepatitis. J Immunol (2005) 1.29
Matrix metalloproteinases: protective roles in cancer. J Cell Mol Med (2011) 1.29
TIMPs and cardiac remodeling: 'Embracing the MMP-independent-side of the family'. J Mol Cell Cardiol (2009) 1.28
Differential expression pattern of membrane-type matrix metalloproteinases in rheumatoid arthritis. Arthritis Rheum (2000) 1.26
Extracellular matrix composition and remodeling in human abdominal aortic aneurysms: a proteomics approach. Mol Cell Proteomics (2011) 1.24
Proteolytic and non-proteolytic roles of membrane type-1 matrix metalloproteinase in malignancy. Biochim Biophys Acta (2009) 1.23
Membrane-type MMPs enable extracellular matrix permissiveness and mesenchymal cell proliferation during embryogenesis. Dev Biol (2007) 1.23
microRNA-9 targets matrix metalloproteinase 14 to inhibit invasion, metastasis, and angiogenesis of neuroblastoma cells. Mol Cancer Ther (2012) 1.22
Extracellular matrix turnover and inflammatory markers independently predict functional status and outcome in chronic heart failure. J Card Fail (2008) 1.20
Individual matrix metalloproteinases control distinct transcriptional responses in airway epithelial cells infected with Pseudomonas aeruginosa. Infect Immun (2007) 1.20
Subcellular distribution and cytokine- and chemokine-regulated secretion of leukolysin/MT6-MMP/MMP-25 in neutrophils. J Biol Chem (2001) 1.20
Molecular structures and dynamics of the stepwise activation mechanism of a matrix metalloproteinase zymogen: challenging the cysteine switch dogma. J Am Chem Soc (2007) 1.19
Activities of the matrix metalloproteinase stromelysin-2 (MMP-10) in matrix degradation and keratinocyte organization in wounded skin. Mol Biol Cell (2004) 1.18
Identification of MMP-9 specific microRNA expression profile as potential targets of anti-invasion therapy in glioblastoma multiforme. Brain Res (2011) 1.17
Collagenase unwinds triple-helical collagen prior to peptide bond hydrolysis. EMBO J (2004) 2.58
Macrophage roles following myocardial infarction. Int J Cardiol (2008) 2.14
Matrix metalloproteinase-28 deletion exacerbates cardiac dysfunction and rupture after myocardial infarction in mice by inhibiting M2 macrophage activation. Circ Res (2012) 1.94
Multi-analyte profiling reveals matrix metalloproteinase-9 and monocyte chemotactic protein-1 as plasma biomarkers of cardiac aging. Circ Cardiovasc Genet (2011) 1.73
Transgenic overexpression of matrix metalloproteinase-9 in macrophages attenuates the inflammatory response and improves left ventricular function post-myocardial infarction. J Mol Cell Cardiol (2012) 1.69
Matrix metalloproteinases and collagen catabolism. Biopolymers (2002) 1.64
The roles of substrate thermal stability and P2 and P1' subsite identity on matrix metalloproteinase triple-helical peptidase activity and collagen specificity. J Biol Chem (2006) 1.49
Effects of early and late chronic pressure overload on extracellular matrix remodeling. Hypertens Res (2008) 1.47
Regulation of collagenase activities of human cathepsins by glycosaminoglycans. J Biol Chem (2003) 1.46
Proteomic analysis identifies in vivo candidate matrix metalloproteinase-9 substrates in the left ventricle post-myocardial infarction. Proteomics (2010) 1.42
Matrix metalloproteinase-9: Many shades of function in cardiovascular disease. Physiology (Bethesda) (2013) 1.41
Altered fibroblast function following myocardial infarction. J Mol Cell Cardiol (2005) 1.37
Angiogenesis in collagen I requires alpha2beta1 ligation of a GFP*GER sequence and possibly p38 MAPK activation and focal adhesion disassembly. J Biol Chem (2003) 1.36
Correlated structural kinetics and retarded solvent dynamics at the metalloprotease active site. Nat Struct Mol Biol (2011) 1.35
Extracellular matrix roles during cardiac repair. Life Sci (2010) 1.32
Extracellular matrix turnover and signaling during cardiac remodeling following MI: causes and consequences. J Mol Cell Cardiol (2009) 1.31
Identification of specific hemopexin-like domain residues that facilitate matrix metalloproteinase collagenolytic activity. J Biol Chem (2009) 1.30
Matrix metalloproteinase-9 deletion attenuates myocardial fibrosis and diastolic dysfunction in ageing mice. Cardiovasc Res (2012) 1.25
Selective hydrolysis of triple-helical substrates by matrix metalloproteinase-2 and -9. J Biol Chem (2003) 1.22
Deletion of thioredoxin-interacting protein in mice impairs mitochondrial function but protects the myocardium from ischemia-reperfusion injury. J Clin Invest (2011) 1.21
Structural basis for matrix metalloproteinase 1-catalyzed collagenolysis. J Am Chem Soc (2012) 1.21
Matrix metalloproteinase (MMP)-9: a proximal biomarker for cardiac remodeling and a distal biomarker for inflammation. Pharmacol Ther (2013) 1.21
Age-related cardiac muscle sarcopenia: Combining experimental and mathematical modeling to identify mechanisms. Exp Gerontol (2007) 1.20
Matrix metalloproteinase triple-helical peptidase activities are differentially regulated by substrate stability. Biochemistry (2004) 1.20
Long-lived ames dwarf mice are resistant to chemical stressors. J Gerontol A Biol Sci Med Sci (2009) 1.18
Selective modulation of matrix metalloproteinase 9 (MMP-9) functions via exosite inhibition. J Biol Chem (2008) 1.15
Effects of deletion of the matrix metalloproteinase 9 gene on development of murine thoracic aortic aneurysms. Circulation (2005) 1.15
CC chemokine receptor 5 deletion impairs macrophage activation and induces adverse remodeling following myocardial infarction. Am J Physiol Heart Circ Physiol (2011) 1.13
Matrix metalloproteinase-28 deletion amplifies inflammatory and extracellular matrix responses to cardiac aging. Microsc Microanal (2011) 1.09
Alterations in cultured myocardial fibroblast function following the development of left ventricular failure. J Mol Cell Cardiol (2006) 1.08
Differentiation of secreted and membrane-type matrix metalloproteinase activities based on substitutions and interruptions of triple-helical sequences. Biochemistry (2007) 1.05
Monoamine oxidase B prompts mitochondrial and cardiac dysfunction in pressure overloaded hearts. Antioxid Redox Signal (2013) 1.04
The left ventricle proteome differentiates middle-aged and old left ventricles in mice. J Proteome Res (2008) 1.04
High throughput screening of potentially selective MMP-13 exosite inhibitors utilizing a triple-helical FRET substrate. Bioorg Med Chem (2008) 1.03
Endorepellin, the C-terminal angiostatic module of perlecan, enhances collagen-platelet responses via the alpha2beta1-integrin receptor. Blood (2006) 1.02
Discovery of novel inhibitors of a disintegrin and metalloprotease 17 (ADAM17) using glycosylated and non-glycosylated substrates. J Biol Chem (2012) 1.02
Exosite interactions impact matrix metalloproteinase collagen specificities. J Biol Chem (2011) 1.02
Extracellular proteases as targets for drug development. Curr Protein Pept Sci (2009) 1.02
Contributions of the MMP-2 collagen binding domain to gelatin cleavage. Substrate binding via the collagen binding domain is required for hydrolysis of gelatin but not short peptides. Matrix Biol (2004) 1.01
Texas 3-step decellularization protocol: looking at the cardiac extracellular matrix. J Proteomics (2013) 1.01
Triple-helical transition state analogues: a new class of selective matrix metalloproteinase inhibitors. J Am Chem Soc (2007) 1.00
Shedding of discoidin domain receptor 1 by membrane-type matrix metalloproteinases. J Biol Chem (2013) 1.00
Neutrophil roles in left ventricular remodeling following myocardial infarction. Fibrogenesis Tissue Repair (2013) 0.99
Myofibroblasts and the extracellular matrix network in post-myocardial infarction cardiac remodeling. Pflugers Arch (2014) 0.98
Polypeptide chains containing D-gamma-hydroxyvaline. J Am Chem Soc (2005) 0.98
A novel conotoxin framework with a helix-loop-helix (Cs alpha/alpha) fold. Biochemistry (2005) 0.98
Catalytic- and ecto-domains of membrane type 1-matrix metalloproteinase have similar inhibition profiles but distinct endopeptidase activities. Biochem J (2004) 0.98
Modulation of triple-helical stability and subsequent melanoma cellular responses by single-site substitution of fluoroproline derivatives. Biochemistry (2002) 0.98
Reduced BDNF attenuates inflammation and angiogenesis to improve survival and cardiac function following myocardial infarction in mice. Am J Physiol Heart Circ Physiol (2013) 0.97
MMP-12 catalytic domain recognizes triple helical peptide models of collagen V with exosites and high activity. J Biol Chem (2008) 0.97
The interface between catalytic and hemopexin domains in matrix metalloproteinase-1 conceals a collagen binding exosite. J Biol Chem (2011) 0.97
Differential modulation of human melanoma cell metalloproteinase expression by alpha2beta1 integrin and CD44 triple-helical ligands derived from type IV collagen. J Biol Chem (2004) 0.96
The normalization of gene expression data in melanoma: investigating the use of glyceraldehyde 3-phosphate dehydrogenase and 18S ribosomal RNA as internal reference genes for quantitative real-time PCR. Anal Biochem (2008) 0.96
Detection of MMP-2 and MMP-9 activity in vivo with a triple-helical peptide optical probe. Bioconjug Chem (2012) 0.96
Transformative Impact of Proteomics on Cardiovascular Health and Disease: A Scientific Statement From the American Heart Association. Circulation (2015) 0.96
Targeted drug delivery utilizing protein-like molecular architecture. J Am Chem Soc (2007) 0.96
Peptide-based selective inhibitors of matrix metalloproteinase-mediated activities. Molecules (2012) 0.95
Examination of matrix metalloproteinase-1 in solution: a preference for the pre-collagenolysis state. J Biol Chem (2013) 0.95
Effects of drug hydrophobicity on liposomal stability. Chem Biol Drug Des (2007) 0.95
In vivo matrix metalloproteinase-7 substrates identified in the left ventricle post-myocardial infarction using proteomics. J Proteome Res (2010) 0.95
Inhibiting metalloproteases with PD 166793 in heart failure: impact on cardiac remodeling and beyond. Cardiovasc Ther (2008) 0.94
Identification of novel, exosite-binding matrix metalloproteinase-13 inhibitor scaffolds. Bioorg Med Chem Lett (2011) 0.94
Toll-like receptor (TLR) 2 and TLR4 differentially regulate doxorubicin induced cardiomyopathy in mice. PLoS One (2012) 0.94
Development of a solid-phase assay for analysis of matrix metalloproteinase activity. J Biomol Tech (2004) 0.94
Local conformation and dynamics of isoleucine in the collagenase cleavage site provide a recognition signal for matrix metalloproteinases. J Biol Chem (2010) 0.94
Triple-helical peptide analysis of collagenolytic protease activity. Biol Chem (2002) 0.94
Characterization of peptide-amphiphiles possessing cellular activation sequences. Biomacromolecules (2003) 0.94
Extracellular matrix and fibroblast communication following myocardial infarction. J Cardiovasc Transl Res (2012) 0.93
Melanoma cell CD44 interaction with the alpha 1(IV)1263-1277 region from basement membrane collagen is modulated by ligand glycosylation. J Biol Chem (2003) 0.93
NMR and bioinformatics discovery of exosites that tune metalloelastase specificity for solubilized elastin and collagen triple helices. J Biol Chem (2010) 0.92
Chemical biology for understanding matrix metalloproteinase function. Chembiochem (2012) 0.92
Characterization of an exosite binding inhibitor of matrix metalloproteinase 13. Protein Sci (2007) 0.90
Substrate conformation modulates aggrecanase (ADAMTS-4) affinity and sequence specificity. Suggestion of a common topological specificity for functionally diverse proteases. J Biol Chem (2006) 0.90
SPARC mediates early extracellular matrix remodeling following myocardial infarction. Am J Physiol Heart Circ Physiol (2011) 0.90
Comparative proteomic analysis of matched primary and metastatic melanoma cell lines. J Proteome Res (2008) 0.90
Mathematical modeling and stability analysis of macrophage activation in left ventricular remodeling post-myocardial infarction. BMC Genomics (2012) 0.89
Getting to the heart of the matter: age-related changes in diastolic heart function in the longest-lived rodent, the naked mole rat. J Gerontol A Biol Sci Med Sci (2012) 0.89
Combining experimental and mathematical modeling to reveal mechanisms of macrophage-dependent left ventricular remodeling. BMC Syst Biol (2011) 0.88
Screening of potential a disintegrin and metalloproteinase with thrombospondin motifs-4 inhibitors using a collagen model fluorescence resonance energy transfer substrate. Anal Biochem (2007) 0.88
Walking the oxidative stress tightrope: a perspective from the naked mole-rat, the longest-living rodent. Curr Pharm Des (2011) 0.88
Citrate synthase is a novel in vivo matrix metalloproteinase-9 substrate that regulates mitochondrial function in the postmyocardial infarction left ventricle. Antioxid Redox Signal (2014) 0.88
Induction of endothelial cell activation by a triple helical alpha2beta integrin ligand, derived from type I collagen alpha1(I)496-507. J Biol Chem (2003) 0.87
Heart failure with preserved ejection fraction: emerging drug strategies. J Cardiovasc Pharmacol (2013) 0.87
Effects of surface-modified scaffolds on the growth and differentiation of mouse adipose-derived stromal cells. J Tissue Eng Regen Med (2007) 0.86
Cardiac extracellular proteome profiling and membrane topology analysis using glycoproteomics. Proteomics Clin Appl (2014) 0.86
Mathematical modeling of left ventricular dimensional changes in mice during aging. BMC Syst Biol (2012) 0.85
Analysis of matrix metalloproteinase triple-helical peptidase activity with substrates incorporating fluorogenic L- or D-amino acids. Anal Biochem (2003) 0.85
Applications of miRNA technology for atherosclerosis. Curr Atheroscler Rep (2014) 0.84
Activity of ADAM17 (a disintegrin and metalloprotease 17) is regulated by its noncatalytic domains and secondary structure of its substrates. J Biol Chem (2013) 0.84
Alterations of pulse pressure stimulate arterial wall matrix remodeling. J Biomech Eng (2009) 0.84
Peptide-mediated targeting of liposomes to tumor cells. Methods Mol Biol (2007) 0.84
Translating Koch's postulates to identify matrix metalloproteinase roles in postmyocardial infarction remodeling: cardiac metalloproteinase actions (CarMA) postulates. Circ Res (2014) 0.84
Proteomic analysis reveals late exercise effects on cardiac remodeling following myocardial infarction. J Proteomics (2010) 0.84
Matrix metalloproteinases: drug targets for myocardial infarction. Curr Drug Targets (2013) 0.84
Amino acid residue Val362 plays a critical role in maintaining the structure of C terminus of connexin 50 and in lens epithelial-fiber differentiation. J Biol Chem (2010) 0.84
Alterations in Pulse Pressure Affect Artery Function. Cell Mol Bioeng (2012) 0.84
Using proteomics to uncover extracellular matrix interactions during cardiac remodeling. Proteomics Clin Appl (2013) 0.83
Cardiac wound healing post-myocardial infarction: a novel method to target extracellular matrix remodeling in the left ventricle. Methods Mol Biol (2013) 0.83
Artery buckling stimulates cell proliferation and NF-κB signaling. Am J Physiol Heart Circ Physiol (2014) 0.83